Astria Therapeutics (ATXS) to Release Earnings on Monday

Astria Therapeutics (NASDAQ:ATXS) is expected to be posting its quarterly earnings results before the market opens on Monday, March 3rd. Analysts expect Astria Therapeutics to post earnings of ($0.45) per share for the quarter.

Astria Therapeutics Trading Down 0.1 %

Shares of ATXS opened at $6.81 on Monday. The business’s fifty day simple moving average is $8.01 and its two-hundred day simple moving average is $10.01. The company has a market cap of $384.29 million, a price-to-earnings ratio of -3.26 and a beta of 0.67. Astria Therapeutics has a 12 month low of $6.64 and a 12 month high of $16.90.

Analyst Upgrades and Downgrades

ATXS has been the topic of several research analyst reports. JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They set an “outperform” rating and a $26.00 price target on the stock. Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Thursday, January 23rd. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $25.67.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.